Post by MPN-MATE Admin » Wed Sep 25, 2019 2:05 am
Hey everyone...
This article is a tad tough to read through because of all the terminologies (jargon) used etc...
However, it is not all that difficult to follow the gist of these findings if one treats it more like an analogy of some mystery and suspense type story.
For example, in Myelofibrosis, Ruxolitinib (Jakafi) is used to suppress the 'Proliferation' of our blood cells, and hopefully thereby create some improvement in Quality of Life (QoL), and maybe even add a few years to our longevity (?) Jakafi therefore works as an Inhibitor (or Blocker) to the Signalling of mutant cells...
Essentially, this article, by a group of Japanese researchers doing the 'Detective' work by planning 'stake-outs' and tracking the movement of their subject groups, (the mutant proteins; inhibitors; chemical compounding treatments; and methods used in those applications), in an endeavour to provide a 'Cause & Effect' at the sub-atomic cellular levels. The Golgi apparatus, which is a transactional part, (organelle), of a cells anatomy:
"The Golgi apparatus, also called Golgi complex or Golgi body, is a membrane-bound organelle found in eukaryotic cells (cells with clearly defined nuclei) that is made up of a series of flattened stacked pouches called cisternae. It is located in the cytoplasm next to the endoplasmic reticulum and near the cell nucleus."
And it doesn't really matter that most of us don't know much about the Golgi at this stage, just that they are a part of a Leukaemic cell's structure. What is important is that we understand it is where much of the cells directions "Oncologic Signals" are coming from, (from those aberrant cellular mutations), and that this newly developed chemical compound, (M-COPA), might be helping to stem proliferation by 'Blocking' their signals to produce more of those aberrant cancer cells etc.
mpn-mate.com/forum/viewtopi...
Best wishes all
Steve